Research Overview
AOD-9604 is a synthetic 15-amino-acid peptide corresponding to amino acids 177 to 191 of the C-terminal end of human growth hormone, modified by addition of a tyrosine residue at the N-terminus to improve stability. Originally developed by Monash University researchers as a means to study the lipolytic domain of the growth hormone molecule in isolation from its growth-promoting activity, AOD-9604 has become a frequently cited research peptide in adipose-tissue and metabolic studies.
Unlike full-length human growth hormone, AOD-9604 does not activate the JAK2-STAT5 signalling pathway associated with growth-promoting effects. Instead, published investigations have focused on its potential influence on lipid mobilisation, adipocyte metabolism and body-composition markers in experimental models.
The peptide is supplied as a 5mg lyophilised powder with documented purity verified by HPLC and mass spectrometry. Each vial is intended exclusively for laboratory and in-vitro research applications and is not intended for human consumption, diagnostic use or veterinary administration.
Mechanism Studied in Research
AOD-9604 is investigated as a fragment that retains the lipolytic-domain activity of full-length human growth hormone while lacking the diabetogenic and growth-promoting effects associated with intact GH. Research has focused on its influence on hormone-sensitive lipase activation, beta-oxidation pathways and adipocyte lipid turnover.
Studies in adipocyte culture systems have reported effects on glycerol release, fatty-acid mobilisation and markers associated with lipid metabolism. Additional investigations have examined downstream signalling pathways involved in energy expenditure and adipocyte differentiation.
Unlike recombinant growth hormone, AOD-9604 does not directly stimulate IGF-1 production. This distinction has made the peptide a useful research tool for separating growth-hormone-associated lipolytic activity from broader endocrine effects in experimental models.
Research Applications
Adipose-tissue and body-composition research. AOD-9604 is frequently investigated in adipocyte cultures and metabolic laboratory models evaluating lipid metabolism, fat-cell signalling and energy expenditure pathways.
Metabolic pathway research. Researchers use AOD-9604 to study lipolysis-related signalling mechanisms and interactions between growth-hormone fragments and adipose-tissue regulatory pathways.
Cartilage and musculoskeletal research. Published experimental investigations have explored the peptide in cartilage-cell and musculoskeletal laboratory models where cellular repair markers and matrix-associated pathways are monitored.
Comparative growth-hormone fragment research. AOD-9604 is often evaluated alongside growth hormone fragments and metabolic research compounds to compare pathway-specific biological activity while avoiding full growth-hormone receptor activation.
Reconstitution Reference
AOD-9604 is supplied as a sterile lyophilised powder in a 5mg vial. Researchers commonly reconstitute the material using bacteriostatic water under laboratory conditions.
A frequently used laboratory example is the addition of 2ml of bacteriostatic water to produce a concentration of 2.5mg/ml. The diluent should be introduced slowly down the inner wall of the vial and the solution allowed to dissolve without vigorous agitation.
The resulting solution should appear clear and free of visible particulate matter. Reconstituted material is typically stored under refrigerated laboratory conditions and protected from repeated freeze-thaw cycles.
Storage and Handling
Lyophilised AOD-9604 is stable when stored sealed at -20°C and protected from light and moisture. Under these conditions, peptide stability is maintained according to batch-specific analytical documentation.
After reconstitution, laboratory protocols generally store the solution at 2-8°C and use it within fourteen to twenty-one days. Repeated freeze-thaw cycles should be avoided as they may reduce peptide integrity.
Researchers should document storage conditions, reconstitution dates and handling procedures within laboratory records to maintain study consistency and traceability.
References
[2] Heffernan M, Summers R, Thornton A, et al. (2004). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese and diabetic KK mice. Endocrinology. PMID 15034263
[3] Heffernan MA, Jiang WJ, Thornton AW, Ng FM. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology Endocrinology and Metabolism. PMID 10920034
[4] Niven DR, Park GW. (2005). Effect of intra-articular injection of AOD9604 with or without vanadyl acetylacetonate in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science. PMID 15945365
[5] Sicer H, Wu S, Kealey D. (2003). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology, Diabetes and Obesity.